Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT03288805
Active, not recruiting Observational

Cohort Study in South China

NCT03288805 · tracked via the Priya Life Science China tracker
Sponsor
Min Xia
Phase
Observational
Started
2017-01-01
Last updated
2022-05-05

Condition(s) studied

Chronic Disease

Study summary

Healthy Chinese residents from South China will be recruited and followed up for at least 4 years to evaluate the association between climate, diet and lifestyle and risks for the development of chronic diseases. Physical examination, questionnaire survey and biological sample collection will be conducted at baseline and the incidence of chronic diseases will be investigated during follow-up.

Eligibility

Sex
ALL
Min age
35 Years
Max age
74 Years
Healthy volunteers
Accepted
Inclusion Criteria: * adult Chinese (35-74 years old) who have been living in South China including Guangdong, Fujian, Guangxi and Hainan provinces for more than 5 years. Exclusion Criteria: * any subject diagnosed with stroke, coronary heart disease, malignancy, chronic obstructive pulmonary disease, diabetes and hypertension. * any subject who suffer from major disability and cannot participate in the study.

Primary outcome measure(s)

  • Incidence of chronic disease — 4 years
    Incidence of chronic disease, including stroke, coronary heart disease, cancer, chronic obstructive pulmonary disease, diabetes and hypertension

Trial sites (1)

FacilityCityRegionStatus
Sun Yat-Sen University Guangzhou Guangdong

More Min Xia trials in China

Cardiovascular Disease Cohort in Guangdong Province Active, not recruiting

Other trials for the same condition

Development and Validation of a Digital Twin-based Clinical Research System (X Town Stage I) Recruiting
Taining Golden Lake Comprehensive Chronic Disease Management Initiative Recruiting
Cohort Study in Fujian Province Recruiting
Whole-life Investigation of Lishui Longevity Recruiting
The Dampness Syndrome of Chinese Medicine Cohort Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03288805 on ClinicalTrials.gov ↗ ← All trials in China